Visit https://www.peervoice.com/BMY860 to view the entire programme with slides. After completing “From P-Values to Patients: A Practical Approach to Managing CKD”, participants will be able to: Describe the rationale for SGLT2 inhibitors in the management of patients with chronic kidney disease (CKD), based on current guidelines and evidence; Develop practical solutions to integrate novel therapies in the management of CKD; Formulate strategies to improve outcomes in CKD

Visit https://www.peervoice.com/VEP860 to view the entire programme with slides. After completing “As COVID Mutates: Clinical Strategies to Stop Viral Spread”, participants will be able to: Describe the potential impact of COVID variants on public health; Identify the benefits and limitations of current clinical tools against COVID variants; Propose practical strategies to reduce the impact of COVID variants on public health and help prevent the development of new variants

Visit https://www.peervoice.com/MCX860 to view the entire programme with slides. After completing “Patient by Patient: Strategies for Managing Lipid-Related Cardiovascular Risk”, participants will be able to: Establish goals of lipid-lowering therapy; Summarise current best practices for managing lipid-related cardiovascular risk; Apply principles of active evaluation and management of lipid-related cardiovascular risk to practice, with the goal of improving outcomes

Visit https://www.peervoice.com/NSN860 to view the entire programme with slides. After completing “Ensuring Long-Term Success in Advanced Ovarian Cancer: Sequencing Therapy Based on Science”, participants will be able to: Identify the diverse factors that can influence treatment decision-making in advanced ovarian cancer; Evaluate recent clinical evidence for PARP inhibitors in the management of advanced ovarian cancer; Translate current and emerging evidence into optimal treatment strategies for patients with advanced ovarian cancer

Visit https://www.peervoice.com/DKF860 to view the entire programme with slides. After completing “Optimising Outcomes With PARPs in Advanced Ovarian Cancer”, participants will be able to: Describe the latest clinical findings for PARP inhibitors in the management of advanced ovarian cancer; Summarise the clinical implications of these emerging data in the management of advanced ovarian cancer; Translate clinical evidence for PARP inhibitors in advanced ovarian cancer into optimal treatment plans

Visit https://www.peervoice.com/JME860 to view the entire programme with slides. After completing “Raising Standard of Care in Psoriatic Arthritis: Is Current Practice Enough?”, participants will be able to: Summarise current standard of care of patients with psoriatic arthritis (PsA); Identify the unmet needs and rationale for raising the standard of care in patients with PsA; Develop clinical protocols to raise the standard of care for patients with PsA

Visit https://www.peervoice.com/UBR860 to view the entire programme with slides. After completing “More Than Skin Deep: The Burden of GPP”, participants will be able to: Differentiate generalised pustular psoriasis (GPP) from plaque psoriasis in terms of phenotype, histopathology, and genetics; Describe the burden of GPP for patients and impact on quality of life; Apply knowledge of GPP to improve patient communication about GPP

Visit https://www.peervoice.com/BRJ860 to view the entire programme with slides. After completing “State of the Science in CKD: New Treatment, New Outcomes”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), with or without type 2 diabetes (T2DM); Summarise the goals of therapy for patients with CKD, based on latest data; Apply updated strategies to the management of CKD, with the goal of improving outcomes and fostering a multidisciplinary approach

Visit https://www.peervoice.com/ZTA860 to view the entire programme with slides. After completing “Novel Targets in T2DM: Incretin Co-Agonists to the Rescue?”, participants will be able to: Discuss emerging clinical evidence for incretin therapies for type 2 diabetes (T2DM) and how these data may impact future management strategies; Describe the function of incretin hormones and their role in the pathogenesis of T2DM; Recognise the benefits of incretin therapies beyond glycaemia control in patients with T2DM

Visit https://www.peervoice.com/BGY860 to view the entire programme with slides. After completing “Conversations in Cardiology: Improving Recognition and Management of Hypertrophic Cardiomyopathy”, participants will be able to: Describe unmet needs in the diagnosis and treatment of patients with hypertrophic cardiomyopathy (HCM); Apply optimal diagnostic strategies to the work-up of HCM, including cardiac imaging modalities; Discuss emerging treatment options for the management of patients with HCM